HOME >> BIOLOGY >> NEWS
Circadian clock genes may provide targets for new cancer drugs

A tumor's growth may be controlled by a complex, gene-controlled "clock"-- and jamming that "clock" can offer a new way to fight cancer, according to two studies presented today at the International Conference on Molecular Targets and Cancer Therapeutics organized by the American Association of Cancer Research (AACR), National Cancer Institute (NCI) and European Organisation for Research and Treatment of Cancer (EORTC) in Boston.

Tumor cell circadian clock genes are rhythmically expressed in coordination with rhythmic circadian growth and thereby may represent new therapeutic targets: Abstract 698

Recent research suggests that at least eight central 'clock' genes coordinate many basic functions such as cell proliferation and apoptosis in circadian time, or within each day, according to researchers from the Dorn Veterans Administration Medical Center and the University of South Carolina. Shaojin You, M.D., Ph.D., assistant professor, and his colleagues undertook the first study to establish a relationship between circadian clock gene expression and the growth rate of tumors.

"These results demonstrate that tumor growth itself, as well as cellular and molecular measures of cancer growth, are organized within circadian time," said Dr. You. "Taken in the context of other recent studies, this work indicates that circadian clock genes and their products potentially represent novel targets for the control of cancer growth."

In these studies, some 30 female mice kept on an alternating 12-hour light and 12-hour dark schedule were injected with tumor cells; the rate of tumor growth was subsequently measured to determine the impact of circadian rhythms.

The results showed that "tumors grew on average twice as fast in the 'daily activity/dark circadian phase' than during the 'sleep/light phase' of the [24 hour] circadian cycle," the team reported. The tumor mitotic index, a measure of the proportion of cancer cells actively dividing,
'"/>

Contact: Warren Froelich
froelich@aacr.org
215-440-9300
American Association for Cancer Research
18-Nov-2003


Page: 1 2 3

Related biology news :

1. Circadian clock genes reign in duration of fruit fly copulation
2. Circadian influence in plants more widespread than previously thought
3. Shedding Light On Circadian Rhythms
4. Two Brandeis Scientists Shed Light On The First Photoreceptor Known To Set Circadian Rhythms
5. Glowing Cyanobacteria Gives Researchers New Clues To Circadian Rhythms
6. Researchers Identify New Component Of Circadian Clock
7. Punching the timeclock of life
8. Analysis of biological clock may lead to greater understanding of human disease
9. Testing the fitness of biological clocks
10. Enzyme activation appears key in helping internal clock tell night from day
11. New clock gene uncovered

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
(Date:3/31/2016)... PROVIDENCE, R.I. , March 31, 2016  Genomics ... leadership of founding CEO, Barrett Bready , M.D., ... addition, members of the original technical leadership team, including ... Vice President of Product Development, Steve Nurnberg and Vice ... have returned to the company. Dr. Bready ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... Andrew D Zelenetz ... Published recently in Oncology ... touchONCOLOGY, Andrew D Zelenetz , discusses the ... is placing an increasing burden on healthcare systems ... With the patents on many biologics expiring, interest ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
Breaking Biology Technology:
Cached News: